Ovid Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (in thousands, except share and per share data) | December 31,2024 | December 31,2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $26,301 | $27,042 |
| Marketable securities | 26,774 | 78,792 |
| Prepaid expenses and other current assets | 2,865 | 3,763 |
| Total current assets | 55,940 | 109,598 |
| Long-term equity investments | 20,974 | 17,626 |
| Restricted cash | 1,931 | 1,931 |
| Right-of-use asset, net | 12,797 | 13,894 |
| Property and equipment, net | 433 | 769 |
| Other assets | 92 | 210 |
| Total assets | $92,167 | $144,027 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,191 | $3,703 |
| Accrued expenses | 5,994 | 6,524 |
| Current portion, lease liability | 1,336 | 1,246 |
| Total current liabilities | 10,522 | 11,473 |
| Long-term liabilities: | ||
| Lease liability | 13,419 | 14,756 |
| Royalty monetization liability | — | 30,000 |
| Total liabilities | 23,941 | 56,230 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 71,009,866 and 70,691,992 shares issued and outstanding at December 31, 2024 and 2023, respectively | 71 | 71 |
| Additional paid-in-capital | 372,489 | 365,591 |
| Accumulated other comprehensive income (loss) | (35) | 1 |
| Accumulated deficit | (304,299) | (277,865) |
| Total stockholders’ equity | 68,226 | 87,797 |
| Total liabilities and stockholders’ equity | $92,167 | $144,027 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.